EDI 200

Drug Profile

EDI 200

Alternative Names: APO-200; EDI200; Fc EDA1; Fc:EDA-A1 fusion protein; Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion protein; Hypohidrotic ectodermal dysplasia therapy - Edimer; Recombinant ectodysplasin A1; Recombinant EDA1; XLHED therapy - Edimer

Latest Information Update: 23 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apoxis
  • Developer Edimer Pharmaceuticals
  • Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Tumour necrosis factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ectodermal dysplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ectodermal dysplasia

Most Recent Events

  • 01 Dec 2015 Edimer Pharmaceuticals completes a phase II trial for Ectodermal dysplasia (in neonates, treatment-naive) in USA, United Kingdom, France, Germany, and Italy (NCT01775462)
  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
  • 24 Jun 2014 Edimer Pharmaceuticals enters into collaboration with InformedDNA for the development of EDI 200
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top